Liver enzyme monitoring in patients treated with troglitazone.

  title={Liver enzyme monitoring in patients treated with troglitazone.},
  author={D. Graham and C. R. Drinkard and D. Shatin and Y. Tsong and M. J. Burgess},
  volume={286 7},
  • D. Graham, C. R. Drinkard, +2 authors M. J. Burgess
  • Published 2001
  • Medicine
  • JAMA
  • CONTEXT Soon after initial marketing in March 1997, troglitazone, the first thiazolidinedione antidiabetic agent, was found to cause life-threatening acute liver failure. The drug was removed from the market in March 2000. OBJECTIVE To evaluate the effect of US Food and Drug Administration (FDA) risk management efforts, including repeated labeling changes and "Dear Healthcare Professional" letters, on periodic liver enzyme monitoring of patients taking troglitazone. DESIGN, SETTING, AND… CONTINUE READING
    147 Citations

    Paper Mentions

    Errors and preventable adverse events associated with medication prescription and dispensing are common, and the difference between guideline recommendations and the actual frequency of… Expand
    InterventionDevice, Procedure
    Troglitazone-induced liver failure: a case study.
    • 162
    Incidence of Idiopathic Acute Liver Failure and Hospitalized Liver Injury in Patients Treated With Troglitazone
    • 57
    Safety of low-dose oral dantrolene sodium on hepatic function.
    • 7
    A study of compliance with FDA recommendations for pemoline (Cylert).
    • 41
    • PDF


    Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
    • 186
    Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
    • 217
    Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.
    • 188
    Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
    • 782
    Severe hepatotoxicity associated with troglitazone.
    • 68
    An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis
    • 90
    A sharper Bonferroni procedure for multiple tests of significance
    • 4,117
    • Highly Influential
    • PDF
    Epidemiology of hepatotoxicity with troglitazone: FDA Metabolic-Endocrine Drugs
    • Advisory Committee Meeting,
    • 1999